We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cardinal Health (CAH) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Cardinal Health (CAH - Free Report) closed the most recent trading day at $159.46, moving -1.02% from the previous trading session. This change lagged the S&P 500's 0.54% gain on the day. At the same time, the Dow added 0.52%, and the tech-heavy Nasdaq gained 0.74%.
The prescription drug distributor's shares have seen a decrease of 2.59% over the last month, not keeping up with the Medical sector's loss of 2.12% and the S&P 500's gain of 4.2%.
The investment community will be closely monitoring the performance of Cardinal Health in its forthcoming earnings report. The company is scheduled to release its earnings on August 12, 2025. The company is predicted to post an EPS of $2.03, indicating a 10.33% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $60.67 billion, up 1.34% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $8.18 per share and a revenue of $223.09 billion, demonstrating changes of +8.63% and 0%, respectively, from the preceding year.
Investors should also pay attention to any latest changes in analyst estimates for Cardinal Health. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.01% higher. Cardinal Health presently features a Zacks Rank of #2 (Buy).
Looking at valuation, Cardinal Health is presently trading at a Forward P/E ratio of 17.5. Its industry sports an average Forward P/E of 17.92, so one might conclude that Cardinal Health is trading at a discount comparatively.
It is also worth noting that CAH currently has a PEG ratio of 1.6. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Dental Supplies industry currently had an average PEG ratio of 1.64 as of yesterday's close.
The Medical - Dental Supplies industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 64, positioning it in the top 26% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CAH in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cardinal Health (CAH) Stock Sinks As Market Gains: What You Should Know
Cardinal Health (CAH - Free Report) closed the most recent trading day at $159.46, moving -1.02% from the previous trading session. This change lagged the S&P 500's 0.54% gain on the day. At the same time, the Dow added 0.52%, and the tech-heavy Nasdaq gained 0.74%.
The prescription drug distributor's shares have seen a decrease of 2.59% over the last month, not keeping up with the Medical sector's loss of 2.12% and the S&P 500's gain of 4.2%.
The investment community will be closely monitoring the performance of Cardinal Health in its forthcoming earnings report. The company is scheduled to release its earnings on August 12, 2025. The company is predicted to post an EPS of $2.03, indicating a 10.33% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $60.67 billion, up 1.34% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $8.18 per share and a revenue of $223.09 billion, demonstrating changes of +8.63% and 0%, respectively, from the preceding year.
Investors should also pay attention to any latest changes in analyst estimates for Cardinal Health. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.01% higher. Cardinal Health presently features a Zacks Rank of #2 (Buy).
Looking at valuation, Cardinal Health is presently trading at a Forward P/E ratio of 17.5. Its industry sports an average Forward P/E of 17.92, so one might conclude that Cardinal Health is trading at a discount comparatively.
It is also worth noting that CAH currently has a PEG ratio of 1.6. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Dental Supplies industry currently had an average PEG ratio of 1.64 as of yesterday's close.
The Medical - Dental Supplies industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 64, positioning it in the top 26% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CAH in the coming trading sessions, be sure to utilize Zacks.com.